- JP-listed companies
- Income statement
【JP:206A】Income statement
Market cap
¥6.7B
P/E ratio
PRISM BioLab develops new drugs that target hard-to-reach protein interactions inside cells, partnering with major pharmaceutical companies like Eisai.
| 2019/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Revenue | 106 | 206 | 59 | 554 | 113 | 306 | 677 |
| Revenue growth (%) | - | ||||||
| Cost of revenue | - | - | - | 19 | 33 | 145 | 408 |
| Gross profit | - | - | - | 535 | 80 | 161 | 270 |
| Gross margin (%) | - | - | - | ||||
| Operating margin (%) | - | - | - | ||||
| Operating expenses | - | - | - | 468 | 577 | 943 | 1,044 |
| Operating income | - | - | - | 67 | -497 | -782 | -774 |
| Income before tax | -145 | -140 | -154 | 79 | -498 | -832 | -748 |
| Pretax margin (%) | -136.6 | -67.9 | -261.4 | 14.2 | -440.6 | -272.1 | -110.5 |
| Provision for income taxes | - | - | - | 1 | 1 | 1 | 2 |
| Effective tax rate (%) | - | - | - | ||||
| Net income | -145 | -143 | -156 | 73 | -527 | -1,050 | -834 |
| Net income margin (%) | |||||||
| Earnings per share | -1,575.61 | -1,469.95 | -1,556.87 | 2.67 | -19.09 | -33.53 | -22.82 |
| Dividend per share | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | ||
| EBITDA margin (%) | - | - | - | - | - |